vs
Aebi Schmidt Holding AG（AEBI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Aebi Schmidt Holding AG的1.5倍（$772.1M vs $528.4M），Revvity净利率更高（12.7% vs 1.7%，领先11.1%），Revvity自由现金流更多（$161.8M vs $29.7M）
埃比施密特集团是一家源自瑞士的跨国企业，主营农业机械、重型工程设备以及市政作业设备的生产制造，产品涵盖运输车、通用作业底盘、扫路车、拖拉机、割草机等，主要应用于市政道路养护等作业场景。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AEBI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$528.4M
净利率更高
RVTY
高出11.1%
1.7%
自由现金流更多
RVTY
多$132.0M
$29.7M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $528.4M | $772.1M |
| 净利润 | $8.8M | $98.4M |
| 毛利率 | 18.9% | — |
| 营业利润率 | 5.2% | 14.5% |
| 净利率 | 1.7% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $-0.18 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEBIRVTY
| Q4 25 | $528.4M | $772.1M | ||
| Q3 25 | $471.3M | $698.9M | ||
| Q2 25 | $277.7M | $720.3M | ||
| Q1 25 | $249.2M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | — | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润AEBIRVTY
| Q4 25 | $8.8M | $98.4M | ||
| Q3 25 | $1.2M | $46.7M | ||
| Q2 25 | $-2.3M | $53.9M | ||
| Q1 25 | $2.1M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | — | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率AEBIRVTY
| Q4 25 | 18.9% | — | ||
| Q3 25 | 20.0% | 53.6% | ||
| Q2 25 | 20.5% | 54.5% | ||
| Q1 25 | 21.4% | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AEBIRVTY
| Q4 25 | 5.2% | 14.5% | ||
| Q3 25 | 3.7% | 11.7% | ||
| Q2 25 | 5.0% | 12.6% | ||
| Q1 25 | 5.8% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率AEBIRVTY
| Q4 25 | 1.7% | 12.7% | ||
| Q3 25 | 0.3% | 6.7% | ||
| Q2 25 | -0.8% | 7.5% | ||
| Q1 25 | 0.8% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）AEBIRVTY
| Q4 25 | $-0.18 | $0.86 | ||
| Q3 25 | $0.02 | $0.40 | ||
| Q2 25 | $-0.06 | $0.46 | ||
| Q1 25 | $0.39 | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.5M | $919.9M |
| 总债务越低越好 | $595.0M | — |
| 股东权益账面价值 | $814.9M | $7.3B |
| 总资产 | $2.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
现金及短期投资AEBIRVTY
| Q4 25 | $98.5M | $919.9M | ||
| Q3 25 | $126.0M | $931.4M | ||
| Q2 25 | $63.6M | $991.8M | ||
| Q1 25 | $47.8M | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务AEBIRVTY
| Q4 25 | $595.0M | — | ||
| Q3 25 | $628.4M | — | ||
| Q2 25 | $441.0M | — | ||
| Q1 25 | $402.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AEBIRVTY
| Q4 25 | $814.9M | $7.3B | ||
| Q3 25 | $812.2M | $7.4B | ||
| Q2 25 | $359.1M | $7.6B | ||
| Q1 25 | $371.3M | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产AEBIRVTY
| Q4 25 | $2.0B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $1.2B | $12.4B | ||
| Q1 25 | $1.1B | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
负债/权益比AEBIRVTY
| Q4 25 | 0.73× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $29.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 5.6% | 21.0% |
| 资本支出强度资本支出/营收 | 0.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.82× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-5.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AEBIRVTY
| Q4 25 | $33.5M | $182.0M | ||
| Q3 25 | $-3.3M | $138.5M | ||
| Q2 25 | $5.3M | $134.3M | ||
| Q1 25 | $-26.6M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流AEBIRVTY
| Q4 25 | $29.7M | $161.8M | ||
| Q3 25 | $-8.6M | $120.0M | ||
| Q2 25 | $3.3M | $115.5M | ||
| Q1 25 | $-29.7M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率AEBIRVTY
| Q4 25 | 5.6% | 21.0% | ||
| Q3 25 | -1.8% | 17.2% | ||
| Q2 25 | 1.2% | 16.0% | ||
| Q1 25 | -11.9% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度AEBIRVTY
| Q4 25 | 0.7% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率AEBIRVTY
| Q4 25 | 3.82× | 1.85× | ||
| Q3 25 | -2.77× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -12.80× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEBI
| Transferred At Point In Time | $281.5M | 53% |
| Transferred Over Time | $246.9M | 47% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
